These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6760 related articles for article (PubMed ID: 2566177)

  • 41. [Suppressive action of the influenza virus on the cellular immune reaction].
    Frolov AF; Borisov VA
    Vopr Virusol; 1988; 33(2):165-9. PubMed ID: 2970718
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of melanoma specific monocyte cytotoxicity in patients receiving BCG immunotherapy.
    Dufour FD; Morton DL
    Surg Forum; 1977; 28():165-7. PubMed ID: 617405
    [No Abstract]   [Full Text] [Related]  

  • 43. Distant cutaneous granulomas after bacille Calmette-Guérin immunotherapy for malignant melanoma: case for direct infection.
    Moff SL; Corey GR; Gottfredsson M
    Clin Infect Dis; 1999 Dec; 29(6):1569-70. PubMed ID: 10585816
    [No Abstract]   [Full Text] [Related]  

  • 44. Immunotherapy of human leukemia.
    Baker MA; Taub RN
    Mt Sinai J Med; 1972; 39(6):548-65. PubMed ID: 4565179
    [No Abstract]   [Full Text] [Related]  

  • 45. Suppressed cellular immunity in mice harboring intraocular melanomas.
    Niederkorn JY
    Invest Ophthalmol Vis Sci; 1984 Apr; 25(4):447-54. PubMed ID: 6608506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
    Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
    Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
    López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
    J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cellular induction mechanism of CD8+ suppressor T cells by DMBA and TPA: formation of CD4+ suppressor-inducer T cells.
    Negoro T; Iinuma F; Watanabe M
    Cell Immunol; 1996 Feb; 167(2):216-23. PubMed ID: 8603430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
    Disis ML; Grabstein KH; Sleath PR; Cheever MA
    Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Effects of Angelica sinensis polysaccharide on cell-mediated immunity].
    Yang TH; Jia M; Mei QB
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Nov; 21(6):782-3, 788. PubMed ID: 16256045
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Active immunotherapy with B.C.G. for recurrent malignant melanoma.
    Gutterman JU; Mavligit G; McBride C; Frei E; Freireich EJ; Hersh EM
    Lancet; 1973 Jun; 1(7814):1208-12. PubMed ID: 4122562
    [No Abstract]   [Full Text] [Related]  

  • 52. Immunotherapy in patients with melanoma.
    Seiger HF; Shingleton WW; Metzgar RS; Buckley CE
    Ann Surg; 1973 Sep; 178(3):352-9. PubMed ID: 4269702
    [No Abstract]   [Full Text] [Related]  

  • 53. Heterogeneity of melanoma-associated antigens detected by sera from patients receiving adjuvant allogeneic tumor vaccine immunotherapy.
    Dent PB; McCulloch PB; Liao SK; Stone BR; Singal DP
    Clin Immunol Immunopathol; 1982 May; 23(2):379-91. PubMed ID: 6980756
    [No Abstract]   [Full Text] [Related]  

  • 54. [Cutaneous, cellular immunity in malignant melanoma].
    Kehrer HC
    Wien Klin Wochenschr; 1991; 103(13):396-7. PubMed ID: 1897233
    [No Abstract]   [Full Text] [Related]  

  • 55. Immunotherapy of cancer: current status.
    Goodnight JE; Morton DL
    Prog Exp Tumor Res; 1980; 25():61-88. PubMed ID: 6986637
    [No Abstract]   [Full Text] [Related]  

  • 56. Requirements for induction of delay hypersensitivity in the chicken.
    Palladino MA; Grebenau MD; Thorbecke GJ
    Dev Comp Immunol; 1978 Feb; 2(1):121-32. PubMed ID: 76579
    [No Abstract]   [Full Text] [Related]  

  • 57. Immunotherapy.
    James DG
    Trans Ophthalmol Soc U K (1962); 1977 Sep; 97(4):468-73. PubMed ID: 364779
    [No Abstract]   [Full Text] [Related]  

  • 58. Immunotherapy for melanoma.
    Vaisrub S
    JAMA; 1973 Sep; 225(10):1242. PubMed ID: 4542440
    [No Abstract]   [Full Text] [Related]  

  • 59. [Study on cellular immunity and immunotherapy of malignant melanoma (author's transl)].
    Ishihara K
    Nihon Hifuka Gakkai Zasshi; 1975 Oct; 85(12):696-8. PubMed ID: 1238716
    [No Abstract]   [Full Text] [Related]  

  • 60. Suppressor effects of histamine on SK/SD delayed hypersensitivity reactions in man and on E-rosette-forming cells.
    Ambanelli U; Ferraccioli GF; Mangenelli P; Vanona GL
    Agents Actions; 1979 Dec; 9(5-6):474-8. PubMed ID: 546170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 338.